CYP8B1

Across TCGA pan-cancer cohorts, CYP8B1 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated CYP8B1 data layer compared with 24 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher CYP8B1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CYP8B1 expression acts as an unfavorable survival marker, although some lineages such as LUSC show a favorable association.

BLCA, LUSC, and SARC are the cancer types where CYP8B1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Median	All	0.149	0.687	.005	21	view →
LUSC	DFS	Median	All	1.000	0.378	.004	14	view →
SARC	DFS	Median	All	0.121	0.611	.041	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

CYP8B1–BLCA (OS)

Open the BLCA breakdown →